{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:50:10Z","timestamp":1794243010584,"version":"4.9.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41433-025-03720-6","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T12:46:00Z","timestamp":1741869960000},"page":"1751-1757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Vogt-Koyanagi-Harada-like disease secondary to anticancer treatment: a multicentre case series"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5325-0415","authenticated-orcid":false,"given":"Cristhian A.","family":"Urzua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Olate-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Schlaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6227-2242","authenticated-orcid":false,"given":"Marion R.","family":"Munk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-9547","authenticated-orcid":false,"given":"Ester","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Garza-Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Sainz-de-la-Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Adan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Pavesio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo E.","family":"Sabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Labbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristobal","family":"Couto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Cuitino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Arellanes-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fuseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Cairoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Curi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-1989","authenticated-orcid":false,"given":"Alejandra","family":"de-la-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0081-7745","authenticated-orcid":false,"given":"Luz Elena","family":"Concha-del-Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"3720_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0412-4","volume":"11","author":"MM Lavezzo","year":"2016","unstructured":"Lavezzo MM, Sakata VM, Morita C, Rodriguez EE, Abdallah SF, da Silva FT, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis. 2016;11:29.","journal-title":"Orphanet J Rare Dis"},{"key":"3720_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1055\/a-0829-6763","volume":"236","author":"S Elahi","year":"2019","unstructured":"Elahi S, Herbort CP Jr. Vogt-Koyanagi-Harada disease and birdshot retinochoroiditis. Similarities and differences. A glimpse into clinicopathology of stromal choroiditis, a perspective and a review. Klin Monbl Augenheilkd. 2019;236:492\u2013510.","journal-title":"Klin Monbl Augenheilkd"},{"key":"3720_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-020-00214-2","volume":"10","author":"CA Urzua","year":"2020","unstructured":"Urzua CA, Herbort C Jr, Valenzuela RA, Abu El-Asrar AM, Arellanes-Garcia L, Schlaen A, et al. Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. 2020;10:23.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"3720_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-022-00293-3","volume":"12","author":"CA Urzua","year":"2022","unstructured":"Urzua CA, Herbort CP Jr, Takeuchi M, Schlaen A, Concha-Del-Rio LE, Usui Y, et al. Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review. J Ophthalmic Inflamm Infect. 2022;12:17.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"3720_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","volume":"131","author":"RW Read","year":"2001","unstructured":"Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647\u201352.","journal-title":"Am J Ophthalmol"},{"key":"3720_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ajo.2021.03.036","volume":"228","author":"Standardization of Uveitis Nomenclature (SUN) Working Group","year":"2021","unstructured":"Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2021;228:205\u201311.","journal-title":"Am J Ophthalmol"},{"key":"3720_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.36401\/JIPO-22-14","volume":"5","author":"AA Mazharuddin","year":"2022","unstructured":"Mazharuddin AA, Whyte AT, Gombos DS, Patel N, Razmandi A, Chaudhry AL, et al. Highlights on ocular toxicity of immune checkpoint inhibitors at a US Tertiary Cancer Center. J Immunother Precis Oncol. 2022;5:98\u2013104.","journal-title":"J Immunother Precis Oncol"},{"key":"3720_CR8","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","volume":"39","author":"S M\u00e9ndez-Mart\u00ednez","year":"2019","unstructured":"M\u00e9ndez-Mart\u00ednez S, Calvo P, Ruiz-Moreno O, Pardi\u00f1as Bar\u00f3n N, Leci\u00f1ena Bueno J, Gil Ruiz MDR, et al. Ocular adverse events associated with MEK inhibitors. Retina. 2019;39:1435\u201350.","journal-title":"Retina"},{"key":"3720_CR9","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/ICU.0000000000000530","volume":"29","author":"RS Moorthy","year":"2018","unstructured":"Moorthy RS, Moorthy MS, Cunningham ET Jr. Drug-induced uveitis. Curr Opin Ophthalmol. 2018;29:588\u2013603.","journal-title":"Curr Opin Ophthalmol"},{"key":"3720_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/CMR.0000000000000505","volume":"28","author":"PT Diamantopoulos","year":"2018","unstructured":"Diamantopoulos PT, Stoungioti S, Anastasopoulou A, Papaxoinis G, Gogas H. Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. Melanoma Res. 2018;28:648\u201351.","journal-title":"Melanoma Res"},{"key":"3720_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","volume":"256","author":"CD Conrady","year":"2018","unstructured":"Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A. Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol. 2018;256:187\u201391.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3720_CR12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1080\/09273948.2019.1583347","volume":"28","author":"CW Noble","year":"2020","unstructured":"Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee JM, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm. 2020;28:854\u20139.","journal-title":"Ocul Immunol Inflamm"},{"key":"3720_CR13","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.3390\/jcm11174993","volume":"11","author":"F Chaudot","year":"2022","unstructured":"Chaudot F, S\u00e8ve P, Rousseau A, Maria ATJ, Fournie P, Lozach P, et al. Ocular inflammation induced by immune checkpoint inhibitors. J Clin Med. 2022;11:4993.","journal-title":"J Clin Med"},{"key":"3720_CR14","doi-asserted-by":"publisher","unstructured":"Nagai R, Yamamoto A, Yoshida A, Mikawa A. Outcome of nivolumab-induced Vogt- Koyanagi-Harada disease-like uveitis in a patient managed without intravenous methylprednisolone therapy. Case Rep Ophthalmol Med. 2023. https:\/\/doi.org\/10.1155\/2023\/9565205.","DOI":"10.1155\/2023\/9565205"},{"key":"3720_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140:509\u201316.","journal-title":"Am J Ophthalmol"},{"key":"3720_CR16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1634\/theoncologist.2016-0456","volume":"22","author":"A Daud","year":"2017","unstructured":"Daud A, Tsai K. Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist. 2017;22:823\u201333.","journal-title":"Oncologist"},{"key":"3720_CR17","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043\u201353.","journal-title":"J Clin Oncol"},{"key":"3720_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3892\/ijmm_00000191","volume":"23","author":"Q Jiang","year":"2009","unstructured":"Jiang Q, Cao C, Lu S, Kivlin R, Wallin B, Chu W, et al. MEK\/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med. 2009;23:771\u20137.","journal-title":"Int J Mol Med"},{"key":"3720_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1089\/jop.2009.0060","volume":"25","author":"W Huang","year":"2009","unstructured":"Huang W, Yang AH, Matsumoto D, Collette W, Marroquin L, Ko M, et al. PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther. 2009;25:519\u201330.","journal-title":"J Ocul Pharmacol Ther"},{"key":"3720_CR20","first-page":"628","volume":"26","author":"J Lim","year":"2018","unstructured":"Lim J, Lomax AJ, Mcneil C, Harrisberg B. Uveitis and papillitis in the setting of dabrafenib and trametinib therapy for metastatic melanoma: a case report. Ocul Immunol Inflamm. 2018;26:628\u201331.","journal-title":"Ocul Immunol Inflamm"},{"key":"3720_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"3720_CR22","unstructured":"U.S. Department of Health and Human Services website. Common terminology criteria for adverse events (CTCAE) v5.0. 2017. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"3720_CR23","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"3720_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.36401\/JIPO-21-9","volume":"4","author":"C Tiu","year":"2021","unstructured":"Tiu C, Shinde R, Pal A, Biondo A, Lee A, Tunariu N, et al. A Wolf in Sheep\u2019s clothing: systemic immune activation post immunotherapy. J Immunother Precis Oncol. 2021;4:189\u201395.","journal-title":"J Immunother Precis Oncol"},{"key":"3720_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3390\/vaccines8040575","volume":"8","author":"M Morgado","year":"2020","unstructured":"Morgado M, Pl\u00e1cido A, Morgado S, Roque F. Management of the adverse effects of immune checkpoint inhibitors. Vaccines. 2020;8:575.","journal-title":"Vaccines"},{"key":"3720_CR26","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","volume":"37","author":"A Daxini","year":"2018","unstructured":"Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37:2579\u201384.","journal-title":"Clin Rheumatol"},{"key":"3720_CR27","doi-asserted-by":"publisher","unstructured":"Evans W, Mathew C, Richardson-May J, Arora R. A Case report of fedratinib-associated uveitis. Cureus. 2024. https:\/\/doi.org\/10.7759\/cureus.52373.","DOI":"10.7759\/cureus.52373"},{"key":"3720_CR28","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1080\/09273948.2020.1766082","volume":"29","author":"RA Parikh","year":"2021","unstructured":"Parikh RA, Chaon BC, Berkenstock MK. Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series. Ocul Immunol Inflamm. 2021;29:1585\u201390.","journal-title":"Ocul Immunol Inflamm"},{"key":"3720_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102454","volume":"111","author":"C Anquetil","year":"2020","unstructured":"Anquetil C, Salem JE, Lebrun-Vignes B, Touhami S, Desbois AC, Maalouf G, et al. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO\u2019s pharmacovigilance database. J Autoimmun. 2020;111:102454.","journal-title":"J Autoimmun"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03720-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03720-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03720-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:24:13Z","timestamp":1748867053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03720-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3720"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03720-6","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}